新型去氟（6）喹诺酮DX-619的体外抗菌活性
In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.
作者信息
Fujikawa Katsuko, Chiba Megumi, Tanaka Mayumi, Sato Kenichi
机构信息
New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., 16-13 Kitakasai 1-Chome, Edogawa-ku, Tokyo 134-8630, Japan.
出版信息
Antimicrob Agents Chemother. 2005 Jul;49(7):3040-5. doi: 10.1128/AAC.49.7.3040-3045.2005.
Abstract
The in vitro activities of DX-619, des-fluoro(6) quinolone, against 1,208 clinical isolates were examined. DX-619 was particularly potent against staphylococci, including ciprofloxacin- and methicillin-resistant strains; the MIC at which 90% of the strains tested were inhibited was 0.5 microg/ml. In addition, DX-619 was also active against gram-negative bacteria.
摘要
对去氟（6）喹诺酮类药物DX - 619针对1208株临床分离菌的体外活性进行了检测。DX - 619对葡萄球菌具有特别强的活性，包括对环丙沙星和耐甲氧西林菌株；90%受试菌株被抑制时的最低抑菌浓度（MIC）为0.5微克/毫升。此外，DX - 619对革兰氏阴性菌也有活性。
相似文献
1
In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.
Antimicrob Agents Chemother. 2005 Jul;49(7):3040-5. doi: 10.1128/AAC.49.7.3040-3045.2005.
2
Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
Antimicrob Agents Chemother. 2005 Aug;49(8):3325-33. doi: 10.1128/AAC.49.8.3325-3333.2005.
3
In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone.
Antimicrob Agents Chemother. 2006 Jun;50(6):2261-4. doi: 10.1128/AAC.01407-05.
4
In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
Antimicrob Agents Chemother. 2001 Jun;45(6):1923-7. doi: 10.1128/AAC.45.6.1923-1927.2001.
5
In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
Antimicrob Agents Chemother. 2004 Jul;48(7):2771-7. doi: 10.1128/AAC.48.7.2771-2777.2004.
6
In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
Antimicrob Agents Chemother. 2001 Dec;45(12):3616-22. doi: 10.1128/AAC.45.12.3616-3622.2001.
7
[In vitro evaluation of lomefloxacin].
Arzneimittelforschung. 1989 Aug;39(8):832-5.
8
Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
Diagn Microbiol Infect Dis. 2007 May;58(1):19-26. doi: 10.1016/j.diagmicrobio.2006.12.009. Epub 2007 Mar 23.
9
Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
J Antimicrob Chemother. 2003 Nov;52(5):869-72. doi: 10.1093/jac/dkg429. Epub 2003 Sep 30.
10
In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
Chemioterapia. 1987 Jun;6(2 Suppl):149-51.
引用本文的文献
1
New Pharmacokinetic and Microbiological Prediction Equations to Be Used as Models for the Search of Antibacterial Drugs.
Pharmaceuticals (Basel). 2022 Jan 20;15(2):122. doi: 10.3390/ph15020122.
2
Effects of statins on multispecies oral biofilm identify simvastatin as a drug candidate targeting Porphyromonas gingivalis.
J Periodontol. 2019 Jun;90(6):637-646. doi: 10.1002/JPER.18-0179. Epub 2018 Dec 26.
3
JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.
J Infect Chemother. 2016 Jul;22(7 Suppl):S1-S65. doi: 10.1016/j.jiac.2015.12.019. Epub 2016 Jun 15.
4
Microbiological and Clinical Effects of Sitafloxacin and Azithromycin in Periodontitis Patients Receiving Supportive Periodontal Therapy.
Antimicrob Agents Chemother. 2016 Jan 4;60(3):1779-87. doi: 10.1128/AAC.02575-15.
5
Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects.
Pharm Res. 2013 Feb;30(2):447-57. doi: 10.1007/s11095-012-0890-6. Epub 2012 Oct 17.
6
Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol.
Antimicrob Agents Chemother. 2007 Jun;51(6):1912-7. doi: 10.1128/AAC.01223-06. Epub 2007 Mar 19.
7
In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone.
Antimicrob Agents Chemother. 2006 Nov;50(11):3908-13. doi: 10.1128/AAC.00639-06.
8
Molecular characteristics and in vitro susceptibility to antimicrobial agents, including the des-fluoro(6) quinolone DX-619, of Panton-Valentine leucocidin-positive methicillin-resistant Staphylococcus aureus isolates from the community and hospitals.
Antimicrob Agents Chemother. 2006 Dec;50(12):4077-86. doi: 10.1128/AAC.00847-06. Epub 2006 Oct 16.
9
Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis.
Antimicrob Agents Chemother. 2006 Dec;50(12):4191-4. doi: 10.1128/AAC.01110-06. Epub 2006 Oct 16.
10
Intracellular penetration and activity of DX-619 in human polymorphonuclear leukocytes.
Antimicrob Agents Chemother. 2006 Sep;50(9):3173-4. doi: 10.1128/AAC.00427-06.
本文引用的文献
1
[In vitro susceptibilites to levofloxacin and various antibacterial agents of 11,475 clinical isolates obtained from 52 centers in 2002].
Jpn J Antibiot. 2005 Feb;58(1):17-44.
2
Vancomycin-resistant Staphylococcus aureus--New York, 2004.
MMWR Morb Mortal Wkly Rep. 2004 Apr 23;53(15):322-3.
3
The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002.
Diagn Microbiol Infect Dis. 2003 Dec;47(4):579-86. doi: 10.1016/s0732-8893(03)00140-8.
4
Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania.
Antimicrob Agents Chemother. 2004 Jan;48(1):275-80. doi: 10.1128/AAC.48.1.275-280.2004.
5
[Activities of antimicrobial agents against 8,474 clinical isolates obtained from 37 medical institutions during 2000 in Japan].
Jpn J Antibiot. 2003 Oct;56(5):341-64.
6
Antimicrobial resistance trends and outbreak frequency in United States hospitals.
Clin Infect Dis. 2004 Jan 1;38(1):78-85. doi: 10.1086/380457. Epub 2003 Dec 8.
7
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.
Am J Infect Control. 2003 Dec;31(8):481-98. doi: 10.1016/j.ajic.2003.09.002.
8
Vancomycin-resistant enterococci in King Chulalongkorn Memorial Hospital: a 5-year study.
J Med Assoc Thai. 2003 Jun;86 Suppl 2:S224-9.
9
Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid.
Clin Infect Dis. 2003 Jun 1;36(11):E146-8. doi: 10.1086/374929. Epub 2003 May 20.
10
Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene.
N Engl J Med. 2003 Apr 3;348(14):1342-7. doi: 10.1056/NEJMoa025025.
Zotero 插件